Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 10;4(7):103720.
doi: 10.1016/j.jscai.2025.103720. eCollection 2025 Jul.

Trends in Percutaneous Closure of Atrial Septal Anomalies: Impact of Landmark Trials Over 20 Years

David M Chye  1   2 , Thalys Sampaio Rodrigues  1   2   3 , Matias B Yudi  1   3 , Julian K Yeoh  1 , Alexandra Murphy  1   4 , Nicholas Jones  1   2   3 , Louise M Burrell  1   2   3 , Vincent Thijs  3   5   6 , Omar Farouque  1   3 , Anoop N Koshy  1   3   7
Affiliations

Trends in Percutaneous Closure of Atrial Septal Anomalies: Impact of Landmark Trials Over 20 Years

David M Chye et al. J Soc Cardiovasc Angiogr Interv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percutaneous closure of atrial septal anomalies in Australia. (A) Cumulative incidence rates of percutaneous closure of atrial septal anomalies (patent foramen ovale/atrial septal defects) by state/territory. (B) Incidence rates of percutaneous closure of atrial septal anomalies (patent foramen ovale/atrial septal defects) by age. ACT, Australian Capital Territory; NSW, New South Wales; NT, Northern Territory; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; WA, Western Australia.
See this image and copyright information in PMC

References

    1. Ropper A.H. Tipping point for patent foramen ovale closure. N Engl J Med. 2017;377(11):1093–1095. doi: 10.1056/NEJMe1709637. - DOI - PubMed
    1. Furlan A.J., Reisman M., Massaro J., et al. CLOSURE I Investigators Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991–999. doi: 10.1056/NEJMoa1707404. - DOI - PubMed
    1. Saver J.L., Carroll J.D., Thaler D.E., et al. RESPECT Investigators Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022–1032. doi: 10.1056/NEJMoa1610057. - DOI - PubMed
    1. Medicare Statistics, Medicare Item Reports [Dataset]. Services Australia. http://medicarestatistics.humanservices.gov.au/statistics/mbs_item.jsp
    1. O'Gara P.T., Messe S.R., Tuzcu E.M., Catha G., Ring J.C., American Heart Association; American Stroke Association; American College of Cardiology Foundation Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation. 2009;119(20):2743–2747. doi: 10.1161/CIRCULATIONAHA.109.192272. - DOI - PubMed

LinkOut - more resources